Heron Beat Fresenius’ Invalidity Claims to Block Cinvanti Copy

Heron Therapeutics Inc. won a ruling blocking Fresenius SE & Co.’s copy of nausea-prevention drug Cinvanti for nearly 11 years because a federal judge rejected the generic-drug maker’s arguments for invalidating two infringed patents, according to an unsealed opinion.

Fresenius failed to prove US Patent Nos. 9,974,794 and 9,561,229 should be voided for covering inventions that would’ve been obvious to skilled practitioners or that lacked adequate written descriptions, according to Judge William C. Bryson’s Dec. 3 findings of fact and conclusions of law unsealed Tuesday in the US District Court for the District of Delaware.

Bryson found Fresenius’ copy infringes ...